Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Sep;30(3):443–452. doi: 10.1111/j.1365-2125.1990.tb03796.x

A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

A Lindholm 1, R Dahlqvist 1, G G Groth 1, F Sjöqvist 1
PMCID: PMC1368148  PMID: 2223423

Abstract

1. Cyclosporine (CsA) concentrations in plasma and whole blood were monitored prospectively in 66 consecutive kidney transplant recipients for 6 months after transplantation or until graft loss. Immunosuppression was based on treatment with CsA and prednisolone in 27 patients and CsA, azathioprine and prednisolone in 39 patients. 2. Whole blood and plasma samples (separated at 37 degrees C) were collected 10-12 h after CsA dosage twice weekly over the first 3 months and thereafter once weekly. CsA concentrations were measured by high pressure liquid chromatography (h.p.l.c.) in plasma, by specific and non-specific monoclonal radioimmunoassays (r.i.a.) in whole blood, and by polyclonal r.i.a. and polyclonal fluorescence polarization immunoassay (f.p.i.a.) in whole blood and plasma. 3. There were no differences between the treatment schedules regarding graft or patient survival, occurrence of acute rejection, nephrotoxicity or infection. 4. CsA concentrations were significantly lower at the time of acute rejection than one week earlier based on all of the analytical methods used except f.p.i.a. 5. The lowest CsA concentration, recorded during the first month after transplantation, was significantly lower in patients with than in patients without experience of acute rejection episodes when the CsA concentrations were measured by polyclonal r.i.a. in whole blood and plasma and by specific and non-specific monoclonal r.i.a. in whole blood, but not by h.p.l.c. in plasma or polyclonal f.p.i.a. in whole blood or plasma. 6. The highest CsA concentration recorded during the second post-transplantation month, was higher in patients with acute nephrotoxicity than in those without nephrotoxicity when CsA was measured by specific monoclonal r.i.a. in whole blood (471 +/- 409 ng ml-1 vs 327 +/- 150 ng ml-1, P less than 0.05), but not by the other methods. 7. The mean plasma h.p.l.c. concentration of CsA measured by h.p.l.c. during the first month after transplantation was significantly higher in patients who suffered from systemic infection than in patients who did not (116 +/- 70 ng ml-1 vs 82 +/- 52 ng ml-1; P less than 0.05). 8. Thus, significant relationships between CsA concentrations and clinical events were apparent using assay methods specific for CsA as well as using polyclonal r.i.a., but not using polyclonal f.p.i.a. When h.p.l.c. was used, however, plasma drug concentrations were often below the limit of determination. Our results suggest that specific analysis of CsA in whole blood allows the best distinction between patients who respond favourably and less favourably to treatment with CsA.

Full text

PDF
443

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertault-Pérès P., Maraninchi D., Carcassonne Y., Cano J. P., Barbet J. Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients. Cancer Chemother Pharmacol. 1985;15(1):76–81. doi: 10.1007/BF00257300. [DOI] [PubMed] [Google Scholar]
  2. Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring. Clin Chem. 1987 Jul;33(7):1269–1288. [PubMed] [Google Scholar]
  3. Donatsch P., Abisch E., Homberger M., Traber R., Trapp M., Voges R. A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981;2(1):19–32. doi: 10.1080/01971528108062989. [DOI] [PubMed] [Google Scholar]
  4. Freed B. M., Rosano T. G., Lempert N. In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation. 1987 Jan;43(1):123–127. doi: 10.1097/00007890-198701000-00027. [DOI] [PubMed] [Google Scholar]
  5. Glerum J. H., Zachariasse D. J., van Dijk A., Jessurun R. F. Changing route of cyclosporin administration: need for close monitoring. Lancet. 1985 Jun 22;1(8443):1447–1448. doi: 10.1016/s0140-6736(85)91874-4. [DOI] [PubMed] [Google Scholar]
  6. Hamilton G., Roth E., Wallisch E., Tichy F. Semi-automated high-performance liquid chromatographic determination of cyclosporine A in whole blood using one-step sample purification and column-switching. J Chromatogr. 1985 Jun 14;341(2):411–419. doi: 10.1016/s0378-4347(00)84054-2. [DOI] [PubMed] [Google Scholar]
  7. Hartman N. R., Jardine I. The in vitro activity, radioimmunoassay cross-reactivity, and molecular weight of thirteen rabbit cyclosporine metabolites. Drug Metab Dispos. 1987 Sep-Oct;15(5):661–664. [PubMed] [Google Scholar]
  8. Hartman N. R., Trimble L. A., Vederas J. C., Jardine I. An acid metabolite of cyclosporine. Biochem Biophys Res Commun. 1985 Dec 31;133(3):964–971. doi: 10.1016/0006-291x(85)91230-6. [DOI] [PubMed] [Google Scholar]
  9. Hayashi Y., Shibata N., Minouchi T., Shibata H., Ono T., Shimakawa H. Evaluation of fluorescence polarization immunoassay for determination of cyclosporin in plasma. Ther Drug Monit. 1989;11(2):205–209. doi: 10.1097/00007691-198903000-00014. [DOI] [PubMed] [Google Scholar]
  10. Holt D. W., Marsden J. T., Johnston A., Bewick M., Taube D. H. Blood cyclosporin concentrations and renal allograft dysfunction. Br Med J (Clin Res Ed) 1986 Oct 25;293(6554):1057–1059. doi: 10.1136/bmj.293.6554.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Holt D. W., Marsden J. T., Johnston A. Measurement of cyclosporine: methodological problems. Transplant Proc. 1986 Dec;18(6 Suppl 5):101–110. [PubMed] [Google Scholar]
  12. Holt D. W., Marsden J. T., Johnston A., Taube D. H. Cyclosporine monitoring with polyclonal and specific monoclonal antibodies during episodes of renal allograft dysfunction. Transplant Proc. 1989 Feb;21(1 Pt 2):1482–1484. [PubMed] [Google Scholar]
  13. Huang W. Y., Lipsey A. I., Cheng M. H. Comparison of cyclosporine determinations in whole blood by three different methods. HPLC, 125I RIA and 3H RIA. Am J Clin Pathol. 1987 Apr;87(4):528–532. doi: 10.1093/ajcp/87.4.528. [DOI] [PubMed] [Google Scholar]
  14. Irschik E., Tilg H., Niederwieser D., Gastl G., Huber C., Margreiter R. Cyclosporin blood levels do correlate with clinical complications. Lancet. 1984 Sep 22;2(8404):692–693. doi: 10.1016/s0140-6736(84)91244-3. [DOI] [PubMed] [Google Scholar]
  15. Kahan B. D., Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 1988 Nov;46(5):631–644. doi: 10.1097/00007890-198811000-00002. [DOI] [PubMed] [Google Scholar]
  16. Kahan B. D. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation. 1985 Nov;40(5):457–476. doi: 10.1097/00007890-198511000-00001. [DOI] [PubMed] [Google Scholar]
  17. Kahan B. D., Wideman C. A., Reid M., Gibbons S., Jarowenko M., Flechner S., Van Buren C. T. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc. 1984 Oct;16(5):1195–1199. [PubMed] [Google Scholar]
  18. Kasiske B. L., Heim-Duthoy K., Rao K. V., Awni W. M. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988 Nov;46(5):716–722. doi: 10.1097/00007890-198811000-00017. [DOI] [PubMed] [Google Scholar]
  19. Kennedy M. S., Yee G. C., Mcguire T. R., Leonard T. M., Crowley J. J., Deeg H. J. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation. 1985 Sep;40(3):249–253. doi: 10.1097/00007890-198509000-00005. [DOI] [PubMed] [Google Scholar]
  20. Keown P. A., Stiller C. R., Ulan R. A., Sinclair N. R., Wall W. J., Carruthers G., Howson W. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet. 1981 Mar 28;1(8222):686–689. doi: 10.1016/s0140-6736(81)91971-1. [DOI] [PubMed] [Google Scholar]
  21. Klintmalm G., Säwe J., Ringdén O., von Bahr C., Magnusson A. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. Transplantation. 1985 Feb;39(2):132–137. doi: 10.1097/00007890-198502000-00005. [DOI] [PubMed] [Google Scholar]
  22. Lindberg A., Odlind B., Tufveson G., Lindström B., Gabrielsson J. The pharmacokinetics of cyclosporine A in uremic patients. Transplant Proc. 1986 Dec;18(6 Suppl 5):144–152. [PubMed] [Google Scholar]
  23. Lindholm A., Lundgren G., Fehrman I., Weibull H., Brynger H., Frödin L., Flatmark A. Influence of early cyclosporine dosage and plasma and whole blood levels on acute rejections in cadaveric renal allograft recipients. Transplant Proc. 1988 Jun;20(3):444–446. [PubMed] [Google Scholar]
  24. Maurer G. Metabolism of cyclosporine. Transplant Proc. 1985 Aug;17(4 Suppl 1):19–26. [PubMed] [Google Scholar]
  25. Ptachcinski R. J., Venkataramanan R., Burckart G. J. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986 Mar-Apr;11(2):107–132. doi: 10.2165/00003088-198611020-00002. [DOI] [PubMed] [Google Scholar]
  26. Ptachcinski R. J., Venkataramanan R., Rosenthal J. T., Burckart G. J., Taylor R. J., Hakala T. R. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther. 1985 Sep;38(3):296–300. doi: 10.1038/clpt.1985.174. [DOI] [PubMed] [Google Scholar]
  27. Quesniaux V., Tees R., Schreier M. H., Maurer G., van Regenmortel M. H. Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine. Clin Chem. 1987 Jan;33(1):32–37. [PubMed] [Google Scholar]
  28. Rogerson M. E., Marsden J. T., Reid K. E., Bewick M., Holt D. W. Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation. 1986 Feb;41(2):276–278. [PubMed] [Google Scholar]
  29. Sanghvi A., Diven W., Seltman H., Starzl T. Abbott's fluorescence polarization immunoassay for cyclosporine and metabolites compared with the Sandoz "Sandimmune" RIA. Clin Chem. 1988 Sep;34(9):1904–1906. [PMC free article] [PubMed] [Google Scholar]
  30. Tredger J. M., Steward C. M., Williams R. Cyclosporine blood levels--an evaluation of radioimmunoassay with selective monoclonal or polyclonal antibodies and high-performance liquid chromatography in liver transplant recipients. Transplantation. 1988 Nov;46(5):681–686. doi: 10.1097/00007890-198811000-00011. [DOI] [PubMed] [Google Scholar]
  31. Vandenbroucke A. C. Evaluation of the TDx method for cyclosporine and a comparison to CYCLO-Trac RIA in renal transplant patients. Clin Biochem. 1988 Oct;21(5):307–309. doi: 10.1016/s0009-9120(88)80086-9. [DOI] [PubMed] [Google Scholar]
  32. Yee G. C., Self S. G., McGuire T. R., Carlin J., Sanders J. E., Deeg H. J. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med. 1988 Jul 14;319(2):65–70. doi: 10.1056/NEJM198807143190201. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES